News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Seattle Biotech NanoString (NSTG)'s Revenue Up 20% as Company Shifts Focus to Cancer Diagnostics



8/5/2015 6:00:54 AM

Seattle biotech NanoString (Nasdaq: NSTG) on Tuesday posted a $12.4 million loss — a loss of 66 cents per share — on a revenue of $13.1 million for the second quarter.

Revenue grew 20 percent compared to the same period last year, when the company posted a $10.9 million revenue. Losses were down year-over-year, from $14 million in the second quarter of 2014.

NanoString develops diagnostic tools to help researchers and drug companies understand what goes wrong in a person's DNA that causes a cancer to develop, and how well treatments work for each individual.

Help employers find you! Check out all the jobs and post your resume.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES